Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Advancing Inclusive Healthcare Strategies Through Social Impact and Sustainability
In this update we examine how Novartis is embedding inclusive healthcare strategies into its core business by launching ambitious long-term Social Impact and Sustainability (SI&S) targets that reach to 2040. These targets integrate innovation, access to medicines, global health, environmental...
Advancing Access: Generic Dapagliflozin Approval Enhanced for Type 2 Diabetes Treatment
The U.S. Food and Drug Administration has issued the generic dapagliflozin approval, clearing the first generic versions of FARXIGA (dapagliflozin) tablets. This decision significantly improves affordability and access to an important SGLT2 inhibitor for adults with type 2 diabetes.
...
Closing the East-West Divide: Addressing Healthcare Investment Disparities in Central and Eastern...
A recent study commissioned by EFPIA and authored by leading CEE academics—Dr. Slaveyko Djambazov, Dr. Luka Voncina, Dr. Aleš Rod, and Dr. Marcin Czech—reveals that despite accelerated public health spending growth in several CEE countries, structural underinvestment persists. This produces marke...